Main menu

Recent Pfizer Press Releases

5/29/14 11:14am EDT
Dr. Morris J. Birnbaum Joins Pfizer as Chief Scientific Officer, Cardiovascular and Metabolic Disease Research

Pfizer Inc. announced that Morris J. Birnbaum, M.D., Ph.D., has joined the company as Chief Scientific Officer for Cardiovascular and Metabolic Disease Research. He will report directly to Rod MacKenzie, Ph.D., Group Senior Vice President and Head of PharmaTherapeutics Research & Development, and will be based in a key Pfizer R&D hub in Cambridge, MA.

more...
5/29/14 8:00am EDT
Pfizer and the Avon Foundation for Women Announce $1 Million Grants Program to Address Gaps in Support for People Living with Metastatic Breast Cancer

·        New National Survey Reveals Lack of Public Knowledge About Metastatic Breast Cancer,1 which Currently Affects Up to 250,000 in the U.S.2

·        Innovative Partnership Will Fund New Projects Focused on Increasing Public Understanding, Enhancing Patient Support

 

 

Despite the high level of public attention devoted to breast cancer awareness, more than 60 percent of respondents in a new national survey commissioned by Pfizer Inc. say they know little to nothing about metastatic breast cancer.1

more...
5/27/14 8:30am EDT
Pfizer Brings Frequent Heartburn Relief Over-the-Counter with New Nexium® 24HR

The nation’s most prescribed acid blocker brand is now available without a prescription at retailers nationwide

Pfizer Inc. (NYSE: PFE) today announced the introduction in the U.S.

more...
5/26/14 10:02am EDT
ANNOUNCEMENT REGARDING ASTRAZENECA PLC

Statement from Pfizer Inc.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

more...
5/23/14 9:13am EDT
Pfizer Announces Detailed Results For Phase 3 OPT Retreatment Study Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis

Findings Presented During 11th European Academy of Dermatology and Venereology Spring Symposium in Belgrade, Serbia

Pfizer Inc. (NYSE:PFE) announced today detailed results from the Oral treatment Psoriasis Trial (OPT) Retreatment study (A3921111), a Phase 3 study investigating tofacitinib for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis.

more...
5/21/14 8:15am EDT
New Survey Highlights The Impact Of Menopausal Symptoms On Women In The Workplace

Key Findings Show What Many Are Doing to ‘Keep Their Cool’

A new national survey released today by Working Mother Media and Pfizer (NYSE:PFE) on the impact of menopausal symptoms on women in the workplace finds that managing menopausal symptoms in their work life is extremely or somewhat difficult for nearly half (48 percent) of working women ages 45-65 who have experienced these symptoms in the past year.

more...
5/19/14 6:41pm EDT
Statement from Pfizer Inc.

FINAL PROPOSAL TO ASTRAZENECA

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

19 May 2014

more...
5/18/14 5:03pm EDT
PFIZER MAKES FINAL PROPOSAL TO ASTRAZENECA

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

STATEMENT FROM PFIZER INC.

5/16/14 12:12pm EDT
Pfizer To Submit Palbociclib New Drug Application With FDA Based On Final Results Of PALOMA-1

Pfizer Inc. today announced that it will submit a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for palbociclib, combined with letrozole, as first-line systemic treatment of post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer.

more...
5/14/14 11:10am EDT
American College of Physicians, CECity, and Pfizer collaborate to increase adult immunization rates

 

Public health initiative aims to increase unacceptably low adult vaccination rates
 

The American College of Physicians (ACP), CECity, and Pfizer Inc. (NYSE:PFE) today announced a new initiative designed to increase adult immunization rates by assisting physicians and other health care providers in strongly recommending appropriate vaccination and tracking adult immunization rates for quality measurement and improvement. The three organizations made the announcement during the annual National Adult Influenza and Immunization Summit meeting being held May 13-15 in Atlanta.

more...
5/13/14 2:05am EDT
STATEMENT FROM PFIZER INC. (“PFIZER”)

 

Pfizer’s Possible Offer for AstraZeneca plc (“AstraZeneca”) Represents Compelling Shareholder Value

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

13 MAY 2014

more...
5/12/14 6:49pm EDT
Pfizer Prices $4.5 Billion Debt Offering

 

Pfizer Inc. (NYSE:PFE) today announced the pricing of a debt offering consisting of five tranches of notes:

more...
5/9/14 10:30am EDT
Pfizer Announces Positive Phase 2 Study Results for Investigational Meningococcal B Vaccine

Pfizer Inc. (NYSE:PFE) announced today the results from two Phase 2 studies of bivalent rLP2086, Pfizer’s recombinant vaccine candidate, currently under development for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds. In both studies, bivalent rLP2086 was observed to generate bactericidal responses, a measurement of functional immune response, against diverse meningococcal serogroup B test strains following either two or three doses

more...
5/5/14 7:00am EDT
Pfizer Reports First-Quarter 2014 Results

more...
5/2/14 2:11am EDT
Pfizer Sends Letter to Rt Hon David Cameron MP Regarding Commitments If Proposed Combination with AstraZeneca is Completed

•        Establishing the combined company’s corporate and tax residence in England

•        Substantial R&D innovation hub in Cambridge to be completed

•        Key scientific leadership in the UK

•        20% of the combined company’s total R&D workforce in the UK going forward

•        Substantial commercial manufacturing facilities retained at Macclesfield

•        European Business Headquarters and European Regulatory Headquarters to be located in the UK

•        At least two AstraZeneca Board Members to join combined company’s Board

•        Board Meetings to be held in the UK as appropriate and meaningful participation in the UK commercial, economic and social community

Pfizer Chairman and Chief Executive Officer, Ian Read, today sent the following letter to the Rt Hon David Cameron MP, with respect to Pfizer’s commitment to the U.K. and its life sciences agenda following the company’s proposal made to AstraZeneca on May 2, 2014.

more...
5/2/14 2:08am EDT
Pfizer Confirms Delivery of Increased Proposal to AstraZeneca

 

·        Proposal represents a substantial premium of 32% for AstraZeneca shareholders[1]

·        Proposal represents a 39% premium to the closing price of £35.86 on 3 January 2014, being the trading day immediately prior to the date of Pfizer’s January proposal

·        AstraZeneca shareholders would receive, for each AstraZeneca share, 1.845 shares in the combined company and 1,598 pence in cash, representing an indicative value of £50.00 ($84.47) per share[2]

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

more...
5/1/14 8:00am EDT
ALO-02 Demonstrates Significant Difference In Pain Scores In Chronic Low Back Pain Patients And Lower Abuse Potential Compared To Immediate-Release Oxycodone In Recreational Opioid Users

Pfizer Inc. (NYSE:PFE) presented results today from three pivotal studies of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules).

more...
4/28/14 7:00am EDT
Pfizer Invites Investors, Analysts And Media To Join Conference Calls Discussing Possible Combination With AstraZeneca

 

Pfizer Inc. will hold analyst and investor calls to discuss its continuing interest in a possible merger transaction with AstraZeneca Plc. at 8:30 AM EDT (1:30 PM GMT) today, April 28, 2014.

more...
4/28/14 2:08am EDT
Pfizer Confirms Prior Discussions with AstraZeneca Regarding a Possible Combination and Its Continuing Interest in a Possible Merger Transaction

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

STATEMENT FROM PFIZER INC. (“PFIZER”)

POSSIBLE OFFER FOR ASTRAZENECA PLC (“ASTRAZENECA”)

more...
4/24/14 10:50am EDT
Pfizer Hosts Annual Meeting of Shareholders Declares 26-Cent Second-Quarter 2014 Dividend

The board of directors of Pfizer Inc. today declared a 26-cent second-quarter 2014 dividend on the company’s common stock, payable June 3, 2014, to shareholders of record at the close of business on May 9, 2014. The second-quarter 2014 cash dividend will be the 302nd consecutive quarterly dividend paid by Pfizer.

more...

Pages